FLT3 and acute myeloid leukemia: Highly expressed on AML LSCs, with higher levels in FLT3-mutated cases. Minimal on HSCs. Attractive target in preclinical models, but expression on some normal progenitors and non-hematopoietic tissues may limit therapeutic specificity